Radar · Immunotherapy in Massachusetts
Best Immunotherapy Companies in Massachusetts, United States
The 183 best Immunotherapy companies in Massachusetts, United States in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Fog Pharmaceuticals.
By Riya SenguptaFinancials
183companies tracked
$12.7Bdisclosed funding
0unicorns
141have raised
FLIAR INTELLIGENCE · IMMUNOTHERAPY × MASSACHUSETTS
Our analysis of 50 Immunotherapy companies
$8.8b in tracked funding; 69% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
50companies analysed
69%cloud-native stacks
2025funding peak (by rounds)
2017median founding year
42median Fliar Index™
5.3Mcombined LinkedIn audience
95%of audience held by top 3
5companies hiring publicly (12 mo)
Ranked: Best Immunotherapy companies in Massachusetts
| # | Company | Disclosed funding | Last round | Employees | Founded | Founder | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|
| 1 | Fog Pharmaceuticals Developer of cell-penetrating mini-proteins to target intracellular disease drivers | $531M | 27 mo ago | 97 97 → 197 (+103%) · sector median +52% | 2015 | — | — | 1 partnership |
| 2 | Odyssey Developer of immunotherapeutics for immunological and cancer diseases 74Funding top 12%Growth top 13%Talent top 28%Moat top 31% All 7 signals ▾Fundingtop 12% Growthtop 13% Talenttop 28% Moattop 31% Techbottom 46% Marketbottom 45% Globalbottom 39% Funding: Raised $503M across 4 rounds · 4 rounds over 5 yrs (0.8/yr) Growth: Headcount 50 → 108 (+116%) across vintages · Fresh capital in last 24 mo rank vs industry peers · Fliar Intelligence Index 74/100 | $503M | 12 mo ago | 108 108 → 118 (+9%) · sector median +52% | 2018 | Paul-Albert König Co-Founder and Sr. Director Biology | — | — |
| 3 | Agenusbio Developer of immunotherapies to treat cancer 60Funding top 20%Tech top 34%Product top 35%Market top 37% All 11 signals ▾Fundingtop 20% Techtop 34% Producttop 35% Markettop 37% Moattop 44% Partnerstop 45% Fin. healthtop 48% Growthtop 50% Newsbottom 47% Talentbottom 40% Globalbottom 39% Funding: Raised $441M across 12 rounds · 12 rounds over 17 yrs (0.7/yr) Tech: 41 technologies across 6/8 capability areas · Cloud: Cloudflare, Fastly rank vs industry peers · Fliar Intelligence Index 60/100 | $441M | 12 mo ago | 533 | 1994 | Garo Armen Chairman & CEO | — | — |
| 4 | Cullinan Oncology Developer of small molecule and vaccine therapeutics for cancer and immunology disorders | $380M | 66 mo ago | 85 | 2017 | — | 22 patents Bispecific therapeutic proteins and heterobifunctional degraders for targeted cancer immunotherapy | — |
| 5 | Ziopharm Oncology Develops immunotherapies for the treatment of cancer and autoimmune diseases | $377M | 81 mo ago | 36 | 2003 | Kevin Boyle CEO | 160 patents Isophosphoramide mustard salt prodrugs for oral cancer therapy, especially glioblastoma. | — |
| 6 | AvenCell Developer of next-generation switchable CAR T-cell immunotherapies 40Funding top 17%Moat top 42%Talent bottom 49%Market bottom 45% All 6 signals ▾Fundingtop 17% Moattop 42% Talentbottom 49% Marketbottom 45% Globalbottom 45% Techbottom 35% Funding: Raised $362M across 4 rounds · 4 rounds over 5 yrs (0.8/yr) Moat: Editorial + unicorn rating 4/10 · Soonicorn rank vs industry peers · Fliar Intelligence Index 40/100 | $362M | 11 mo ago | 67 | 2021 | Andrew Schiermeier Chief Executive Officer | — | — |
| 7 | Affinivax Developer of technology-based conjugate vaccines against infectious diseases | $359M | 65 mo ago | 132 | 2013 | — | 66 patents Multivalent pneumococcal conjugate vaccines and immunogenic polysaccharide-protein compositions | — |
| 8 | Obsidian Therapeutics Developer of engineered cell and gene therapies for multiple diseases | $325M | 26 mo ago | 80 80 → 105 (+31%) · sector median +52% | 2015 | Michael Gilman CEO | 158 patents Engineered cytokine fusion proteins and regulated cell‑therapy platforms for cancer immunotherapy | — |
| 9 | Cullinan Therapeutics Developer of modality-agnostic targeted therapeutics for cancer and autoimmune indications | $280M | 26 mo ago | — | 2020 | Karl Wittrup Co-founder | — | — |
| 10 | Be Bio Developer of B cell therapies for multiple therapeutic areas 50Funding top 22%Moat top 31%Market top 48%Global bottom 36% All 4 signals ▾Fundingtop 22% Moattop 31% Markettop 48% Globalbottom 36% Funding: Raised $264M across 4 rounds · 4 rounds over 6 yrs (0.7/yr) Moat: Editorial + unicorn rating 8/10 · Soonicorn rank vs industry peers · Fliar Intelligence Index 50/100 | $264M | 17 mo ago | 103 | 2020 | — | — | — |
| 11 | Abcuro Developer of immune-modulatory bio-therapeutics for autoimmune diseases and cancer 42Funding top 22%Moat top 28%Growth top 35%Patents top 35% All 9 signals ▾Fundingtop 22% Moattop 28% Growthtop 35% Patentstop 35% Innovationtop 36% Globalbottom 42% Marketbottom 32% Techbottom 19% Newsbottom 17% Funding: Raised $252M across 6 rounds · 6 rounds over 10 yrs (0.6/yr) Moat: Editorial + unicorn rating 8/10 · IP moat: 48 patents rank vs industry peers · Fliar Intelligence Index 42/100 | $252M | 16 mo ago | 24 24 → 40 (+67%) · sector median +52% | 2015 | — | 48 patents Therapeutic anti‑KLRG1 antibodies for treating immune‑cell malignancies and autoimmune diseases | — |
| 12 | Compass Therapeutics Antibody discovery and development company | $239M | 71 mo ago | 32 32 → 58 (+81%) · sector median +52% | 2013 | — | 136 patents Immuno‑oncology antibodies and multispecific checkpoint modulators for cancer therapy | — |
| 13 | Xilio Therapeutics Developer of immunotherapies for the treatment of cancer 67Funding top 25%Growth top 27%Moat top 28%Fin. health top 41% All 9 signals ▾Fundingtop 25% Growthtop 27% Moattop 28% Fin. healthtop 41% Markettop 43% Techtop 45% Talentbottom 49% Newsbottom 46% Globalbottom 39% Funding: Raised $233M across 5 rounds · 5 rounds over 10 yrs (0.5/yr) Growth: Headcount 30 → 72 (+140%) across vintages · Revenue +590% YoY rank vs industry peers · Fliar Intelligence Index 67/100 | $233M | 16 mo ago | 72 72 → 96 (+33%) · sector median +52% | 2016 | Rene Russo CEO | — | — |
| 14 | Merrimack Pharmaceuticals Developing antibodies (monoclonal & polyclonal), antibody drug conjugates, and nanoliposomes for a… | $230M | 95 mo ago | 65 | 2000 | — | 757 patents Immuno‑oncology: TNFR2 antibodies, ATR kinase inhibitors, and liposomal chemo formulations | — |
| 15 | Triveni Bio Developer of functional antibodies for the treatment of immunological and inflammatory disorders | $207M | 20 mo ago | — | 2023 | Vishal Patel CEO | — | — |
| 16 | iTeos Therapeutics Developer of immunotherapy for treating cancer | $204M | 74 mo ago | 32 | 2011 | Michel Detheux Co-founder | — | — |
| 17 | Syndax Developer of targeted therapies for the treatment of cancer | $195M | 76 mo ago | 107 | 2005 | — | — | 1 internship · 1 partnership · 1 award |
| 18 | Pyxis Oncology Developer of antibody therapeutics for treating cancer | $194M | 27 mo ago | 50 50 → 68 (+36%) · sector median +52% | 2019 | Thomas Gajewski Co-Founder | 10 patents Targeted antibody‑drug conjugates against KLRC1, GPNMB, and fibronectin‑EDB cancer biomarkers. | — |
| 19 | Affini-T Therapeutics Developer of T-cell therapies against oncogenic driver mutations | $193M | 22 mo ago | 97 | 2020 | Jak Knowles Co-founder | — | — |
| 20 | Nuvalent Developer of therapeutic solutions for the treatment of cancer | $185M | 61 mo ago | 92 | 2017 | James Porter CEO | 99 patents Macrocyclic heteroaromatic ether anticancer agents targeting EGFR-mutant solid tumors | — |
| 21 | TScan Therapeutics Developer of T cell therapies to harness the immune system against cancer | $180M | 64 mo ago | 154 154 → 151 (-2%) · sector median +52% | 1995 | — | 162 patents Targeted binding protein therapeutics for cancer immunotherapy and hematologic malignancies | 1 launch · 1 partnership |
| 22 | Checkmate Pharmaceuticals Science-driven biopharmaceutical company discovering, developing, and commercializing medicines for serious… | $175M | 72 mo ago | 16 | 2015 | — | — | — |
| 23 | BeiGene Developer of targeted and immune-oncology drugs against cancer | $172M | 71 mo ago | 1,090 | 2010 | John Oyler Founder & CEO | 39 patents Combination therapies targeting MAPK pathway and immune checkpoints for cancer treatment | — |
| 24 | Decibel Therapeutics Developer of new medicines to protect, repair and restore hearing capacity | $170M | 67 mo ago | 62 | 2015 | — | 234 patents Patents concentrated in chemistry & materials | — |
| 25 | Vigil Developer of therapeutic solutions for treating multiple neurodegenerative diseases | $140M | 23 mo ago | 56 | 2020 | Ivana Liebisch CEO & President | — | — |
| 26 | Harpoon Therapeutics Developer of T-cell antibodies against hematologic and solid tumor targets | $130M | 31 mo ago | 93 | 2015 | — | 363 patents Patents concentrated in chemistry & materials | — |
| 27 | OncXerna Developer of therapeutics to treat cancer | $126M | 51 mo ago | 18 | 1996 | — | — | — |
| 28 | Myeloid Therapeutics Developer of myeloid therapeutics solutions for treating cancer and other diseases | $123M | 37 mo ago | 29 29 → 44 (+52%) · sector median +52% | 2019 | Siddhartha Mukherje Founder | 179 patents Cell‑specific gene therapy delivery systems and engineered fusion protein therapeutics. | — |
| 29 | NextPoint Therapeutics Developer of immuno-therapeutics for cancer treatment | $122M | 28 mo ago | 11 | 2019 | — | — | — |
| 30 | Abata Developer of cell therapies for autoimmune and inflammatory disease | $110M | 22 mo ago | 50 | 2021 | Samantha Singer President & Chief Executive Officer | — | — |
| 31 | Totus Medicines Provider of genome-scale drug discovery platform to treat multiple diseases | $108M | 30 mo ago | 23 23 → 35 (+52%) · sector median +52% | 2019 | Neil Dhawan Founder & CEO | 59 patents Patents concentrated in health & consumer products | — |
| 32 | Q32 Bio Developer of drugs for treating autoimmune disorders | $106M | 26 mo ago | 34 34 → 29 (-15%) · sector median +52% | 2018 | Shelia Violette Founder & CSO | — | — |
| 33 | Corner Therapeutics Developer of immuno-therapeutics to treat cancer 24Funding top 34%Moat top 42%Talent top 45%Global bottom 32% All 5 signals ▾Fundingtop 34% Moattop 42% Talenttop 45% Globalbottom 32% Marketbottom 31% Funding: Raised $105M across 3 rounds · 3 rounds over 3 yrs (1.0/yr) Moat: Editorial + unicorn rating 4/10 · Soonicorn rank vs industry peers · Fliar Intelligence Index 24/100 | $105M | 8 mo ago | 16 16 → 28 (+75%) · sector median +52% | 2019 | Andrew Bellinger Co-Founder | — | — |
| 34 | Scholar Rock Developer of Antibody-based drugs for the treatment of primary myopathies | $103M | 48 mo ago | 150 150 → 342 (+128%) · sector median +52% | 2012 | Nagesh Mahanthappa Founding CEO & President | 512 patents Therapeutic myostatin and GLP‑1 pathway modulation for metabolic and muscle disorders | 1 launch |
| 35 | Dianthus Therapeutics Developer of antibody therapeutics to treat rare autoimmune diseases | $100M | 50 mo ago | 27 | 2019 | Marino Garcia President & Chief Executive Officer | — | 1 job opening · 1 launch |
| 36 | Tectonic Therapeutic Developer of GPCR-targeted therapies | $80M | 16 mo ago | 28 28 → 69 (+146%) · sector median +52% | 2019 | — | — | — |
| 37 | Crossbow Developer of antibody therapies for cancer treatment 42Funding top 21%Moat top 36%News top 38%Talent top 38% All 8 signals ▾Fundingtop 21% Moattop 36% Newstop 38% Talenttop 38% Innovationtop 48% Patentsbottom 49% Globalbottom 39% Marketbottom 35% Funding: Raised $80.0M across 3 rounds · 3 rounds over 3 yrs (1.0/yr) Moat: Editorial + unicorn rating 4/10 · IP moat: 21 patents rank vs industry peers · Fliar Intelligence Index 42/100 | $80M | 3 mo ago | 24 | 2021 | Geraldine Paulus Co-Founder | 21 patents High‑precision MEMS inertial sensors and power‑efficient wireless tracking technologies | — |
| 38 | Hillstar Bio Developer of precision immunotherapies for autoimmune diseases | $67M | 14 mo ago | — | 2023 | Robert Mabry CEO | — | — |
| 39 | Normunity Developer of immunotherapies for the treatment of cancer | $65M | 17 mo ago | 19 | 2020 | Lieping Chen Co-Founder | 4 patents Therapeutic antibodies targeting KLK6, LY6K, and PLA2G10 for disease treatment | — |
| 40 | Prologue Medicines Developer of therapeutic potential of viral proteins to create transformative medicines | $50M | 25 mo ago | — | 2023 | Hozefa Bandukwala Co-Founder & Chief Innovation Officer | — | — |
| 41 | Cue Biopharma Precision immunotherapies to transform patients' lives by selectively modulating the immune system 67Innovation top 16%Patents top 16%News top 28%Moat top 29% All 11 signals ▾Innovationtop 16% Patentstop 16% Newstop 28% Moattop 29% Growthtop 31% Partnerstop 32% Fundingtop 36% Fin. healthtop 37% Marketbottom 49% Globalbottom 35% Techbottom 32% Innovation: 491 patents (top 5% of patent-holders) · 336 filings since 2022 vs 155 in 2017-21 Patents: 491 patents matched (strict assignee match) · 336 filings since 2022 vs 155 in 2017-21 rank vs industry peers · Fliar Intelligence Index 67/100 | $26M | 1 mo ago | 51 51 → 39 (-24%) · sector median +52% | 2015 | — | 491 patents T-cell engaging biologics for immune modulation and B-cell depletion therapies | — |
| 42 | Leap Therapeutics Developing targeted and immuno-oncology therapeutics for cancer patients 35Product top 14%Funding top 30%Innovation top 34%Tech top 49% All 10 signals ▾Producttop 14% Fundingtop 30% Innovationtop 34% Techtop 49% Moatbottom 45% Newsbottom 42% Growthbottom 39% Globalbottom 37% Marketbottom 35% Fin. healthbottom 30% Product: 4 distinct product lines · Company stage: Public Funding: Raised $24.7M across 7 rounds · 7 rounds over 15 yrs (0.5/yr) rank vs industry peers · Fliar Intelligence Index 35/100 | $25M | 8 mo ago | 44 | 2011 | — | — | — |
| 43 | Minerva Biotechnologies Developer of cell therapy and antibodies to treat cancer | $19M | 31 mo ago | 24 | 1999 | — | 480 patents Therapeutic/diagnostic MUC1 antibodies, NME7 bacterial enzymes, stem‑cell dopaminergic neuron production | — |
| 44 | Ingenia Therapeutics Provider of healthcare therapeutic services | $12M | 24 mo ago | — | 2018 | Sangyeul Han Founder & CEO | — | — |
| 45 | Signa Blok Developer of peptide therapeutics targeting receptor signaling 32Funding top 42%Innovation top 43%Product bottom 44%Market bottom 37% All 5 signals ▾Fundingtop 42% Innovationtop 43% Productbottom 44% Marketbottom 37% Globalbottom 29% Funding: Raised $7.3M across 15 rounds · 15 rounds over 14 yrs (1.1/yr) Innovation: 2 product lines rank vs industry peers · Fliar Intelligence Index 32/100 | $7M | 14 mo ago | — | 2009 | — | — | — |
| 46 | Thymmune Developer of immunetherapeutics for immune-disorders | $7M | 13 mo ago | 9 | 2019 | Stan Wang Founder & CEO | — | 2 job openings |
| 47 | Attivare Therapeutics Developer of immuno-therapeutics for oncology and infectious diseases | $7M | 6 mo ago | 8 | 2020 | Ed Doherty Co-Founder & CTO | — | — |
| 48 | LAPIX Developer of immunotherapies for immunological diseases | $3M | 10 mo ago | 9 | 2019 | Anas Fathallah Co-Founder & CEO | — | — |
| 49 | Angiex Developer of antibody-drug conjugates to treat cancer and cardiovascular diseases | $3M | 10 mo ago | 5 | 2015 | Paul Jaminet Founder & CEO | 62 patents Targeted antibody‑drug and antibody‑oligonucleotide conjugates for TM4SF1 cancer therapy | — |
| 50 | Accurius Developer of oncolytic immunotherapy for metastatic non-small cell lung cancer | $3M | 15 mo ago | — | 2019 | Dmitriy Zamarin Co-Founder & CMO | — | — |
Top 12 Immunotherapy companies in Massachusetts
#1
Series B · Cambridge, Massachusetts · founded 2021 · 24 employees$80Mraised▾
Series B · Cambridge, Massachusetts · founded 2021 · 24 employees
Developer of antibody therapies for cancer treatment. The company is advancing the development of novel therapies that potently target peptide-loaded major histocompatibility complexes (pMHCs) on cancer cells, using antibodies that mimic T-cell receptors (TCR-mimetics).
Fliar Intelligence Index™ 42how this company ranks against its industry peers
Funding
top 21%Moat
top 36%News
top 38%Talent
top 38%Innovation
top 48%Patents
bottom 49%Funding: Raised $80.0M across 3 rounds · 3 rounds over 3 yrs (1.0/yr) · Last round Series B (Mar 2026)
Moat: Editorial + unicorn rating 4/10 · IP moat: 21 patents · Soonicorn
News: 3 BI events in 12 mo (of 4 tracked, 2 types) · Top themes: Funding
Audience (LinkedIn): 6k LinkedIn followers
Funding rounds
- Mar 2026Series B$77M
- Sep 2025Series A$30.2M
- Jul 2023Series A$80M
Founders & team
Investors
Pfizer, Polaris Partners, BVF Partners, Mirae Asset Venture Investments, Mirae Asset, Lilly
#2
Public · Cambridge, Massachusetts · founded 2015 · 51 employees$26.4Mraised▾
Public · Cambridge, Massachusetts · founded 2015 · 51 employees
Precision immunotherapies to transform patients' lives by selectively modulating the immune system. It is a biotechnology company engineering biologics designed to selectively engage and modulate targeted T cells. The company focuses on autoimmune diseases and cancer, aiming to restore immune balance. Their proprietary Immuno-STAT platform enhances a patient’s immune system to potentially restore health. They are developing a novel class of therapeutic biologics. The company's approach involves precision medicine, clinical development, and translational research. They are working towards establishing a new standard of care for diseases that cause human suffering and mortality. They are mobilizing the patient’s immune system to treat serious diseases.
Fliar Intelligence Index™ 67how this company ranks against its industry peers
Innovation
top 16%Patents
top 16%News
top 28%Moat
top 29%Growth
top 31%Partners
top 32%Innovation: 491 patents (top 5% of patent-holders) · 336 filings since 2022 vs 155 in 2017-21
Patents: 491 patents matched (strict assignee match) · 336 filings since 2022 vs 155 in 2017-21 · Latest publication 2026
News: 16 BI events in 12 mo (of 40 tracked, 7 types) · +45% YoY · Top themes: Board, Leadership, Earnings
Audience (LinkedIn): 5k LinkedIn followers
Funding rounds
- May 2026Post IPO$30M
- Nov 2022Post IPO$30M
- Dec 2016Series A$16.4M
- Jun 2015Seed$10M
Investors
MDB Capital
Tech stack
Google AnalyticsGoogle Font ApiJqueryJquery MigrateModernizrMysql
#3
Public · Cambridge, Massachusetts · founded 2018 · 108 employees$503.2Mraised▾
Public · Cambridge, Massachusetts · founded 2018 · 108 employees
Developer of immunotherapeutics for immunological and cancer diseases. It offers anti-inflammation immunotherapies such as anti-TNF antibodies and JAK inhibitors for inflammatory diseases and cancer. It has a computational drug discovery platform.
Fliar Intelligence Index™ 74how this company ranks against its industry peers
Funding
top 12%Growth
top 13%Talent
top 28%Moat
top 31%Tech
bottom 46%Market
bottom 45%Funding: Raised $503M across 4 rounds · 4 rounds over 5 yrs (0.8/yr) · Last round Series D (Jun 2025)
Growth: Headcount 50 → 108 (+116%) across vintages · Fresh capital in last 24 mo
Talent: 3 named leaders on record · 3 C-suite/founder profiles curated
Audience (LinkedIn): 15k LinkedIn followers
Funding rounds
- Jun 2025Series D$214M
- Oct 2023Series C$117.2M
- Oct 2022Series B$168M
- Dec 2021Series A$218M
Founders & team
Investors
General Catalyst, Alexandria, Walleye, Catalio Capital Management, GreatPoint Ventures, SVB Securities
Tech stack
Apple Icloud MailCdnjsCloudflareCloudflare Bot ManagementCookieyesCore-Js
#4
Public · Lexington, Massachusetts · founded 1994 · 533 employees$440.7Mraised▾
Public · Lexington, Massachusetts · founded 1994 · 533 employees
Developer of immunotherapies to treat cancer. The company's portfolio consists of bio-engineered therapies targeting complementary mechanisms to fight cancer, including checkpoint inhibitors, immune activators, and tumor microenvironment conditioning agents.
Fliar Intelligence Index™ 60how this company ranks against its industry peers
Funding
top 20%Tech
top 34%Product
top 35%Market
top 37%Moat
top 44%Partners
top 45%Funding: Raised $441M across 12 rounds · 12 rounds over 17 yrs (0.7/yr) · Last round Post IPO (Jun 2025)
Tech: 41 technologies across 6/8 capability areas · Cloud: Cloudflare, Fastly · Devops: Nginx, Varnish
Product: 0 product launch events in 12 mo · Company stage: Public
Audience (LinkedIn): 45k LinkedIn followers
Funding rounds
- Jun 2025Post IPO—
- Jul 2020Post IPO$35M
- Jan 2019Post IPO$30M
- Oct 2018Post IPO$40M
Founders & team
Investors
Betta Pharmaceuticals, HealthCare Royalty Partners, Incyte, Zynext Ventures, Grazia Equity, Advent Life Sciences
Tech stack
CloudflareComplianzDocusignElementorFancyboxFastly
#5
Series B · Watertown, Massachusetts · founded 2021 · 67 employees$362Mraised▾
Series B · Watertown, Massachusetts · founded 2021 · 67 employees
Developer of next-generation switchable CAR T-cell immunotherapies. This company develops allogeneic platforms to address shortcomings of current T cell-based immunotherapies. Their technology offers powerful controllability of CAR-T reactivity while maintaining high anti-tumor activity. A switchable on/off mechanism, using universal effector cells and soluble adaptors, allows precise targeting of cancer antigens. Rapid switchability lowers the risk of side effects, improving the therapeutic window and safety. The focus is on overcoming limitations of current CAR-T cell therapies.
Fliar Intelligence Index™ 40how this company ranks against its industry peers
Funding
top 17%Moat
top 42%Talent
bottom 49%Market
bottom 45%Global
bottom 45%Tech
bottom 35%Funding: Raised $362M across 4 rounds · 4 rounds over 5 yrs (0.8/yr) · Last round Grant (prize money) (Jul 2025)
Moat: Editorial + unicorn rating 4/10 · Soonicorn · 10 curated direct competitors tracked
Talent: 1 named leader on record · 1 C-suite/founder profile curated
Audience (LinkedIn): 4k LinkedIn followers
Funding rounds
- Jul 2025Grant (prize money)$40M
- Oct 2024Series B$112M
- Feb 2023Grant (prize money)$284.1K
- Jun 2021Series A$250M
Founders & team
Investors
Novo Holdings, Blackstone, F-Prime Capital, Eight Roads Ventures, Piper Sandler, NYBC Ventures
Tech stack
Apple Icloud MailCookiebotCore-JsElementorFont AwesomeGodaddy
#6
Series B · Watertown, Massachusetts · founded 2019 · 16 employees$104.9Mraised▾
Series B · Watertown, Massachusetts · founded 2019 · 16 employees
Developer of immuno-therapeutics to treat cancer. It offers a proprietary chemical mimic called dendritic cell hyperactivation, which stimulates protective immunity through the production of polyclonal populations of long-lived memory T cells.
Fliar Intelligence Index™ 24how this company ranks against its industry peers
Funding
top 34%Moat
top 42%Talent
top 45%Global
bottom 32%Market
bottom 31%Funding: Raised $105M across 3 rounds · 3 rounds over 3 yrs (1.0/yr) · Last round Series B (Sep 2025)
Moat: Editorial + unicorn rating 4/10 · Soonicorn · 10 curated direct competitors tracked
Talent: 4 named leaders on record · 4 C-suite/founder profiles curated · 1 leadership moves in 12 mo
Audience (LinkedIn): 5k LinkedIn followers
Funding rounds
- Sep 2025Series B$16.8M
- Apr 2024Series A$58.5M
- May 2023Series A$58.5M
Founders & team
Investors
Ziff Capital Partners, Cockrell Interests, Tanis Ventures, Sandiaholdings
#7
Series C · Newton, Massachusetts · founded 2015 · 24 employees$251.8Mraised▾
Series C · Newton, Massachusetts · founded 2015 · 24 employees
Developer of immune-modulatory bio-therapeutics for autoimmune diseases and cancer. It offers ABC008 an anti-KLRG1 antibody for autoimmune muscle disease inclusion body myositis, T cell large granular lymphocytic leukemia, and mature T cell malignancies, ABC015 is a monoclonal antibody for cancer treatment.
Fliar Intelligence Index™ 42how this company ranks against its industry peers
Funding
top 22%Moat
top 28%Growth
top 35%Patents
top 35%Innovation
top 36%Global
bottom 42%Funding: Raised $252M across 6 rounds · 6 rounds over 10 yrs (0.6/yr) · Last round Series C (Feb 2025)
Moat: Editorial + unicorn rating 8/10 · IP moat: 48 patents · Soonicorn
Growth: Fresh capital in last 24 mo
Audience (LinkedIn): 4k LinkedIn followers
Activity (LinkedIn): 1 awards announced in 12 mo
Funding rounds
- Feb 2025Series C$200M
- Aug 2023Series B$199.5M
- Jan 2021Series A$42M
- Aug 2019Grant (prize money)$164.1K
Investors
ShangPharma Innovation, Kaitai Capital Management, Sanofi Ventures, Pontifax, Hongsen Investment, RA Capital Management
Tech stack
Apache Http ServerDocusignGenesis ThemeGodaddyGoogle Font ApiJquery
#8
Public · Waltham, Massachusetts · founded 2016 · 72 employees$233Mraised▾
Public · Waltham, Massachusetts · founded 2016 · 72 employees
Developer of immunotherapies for the treatment of cancer. The company is developing its proprietary technology to create an IO therapy that is activated selectively within the tumor. The product XTX201 (IL-2) induces immune activity in tumors without the toxicity seen with non-selective IL-2s, XTX101, XTX301, and XTX401 demonstrates antitumor activity.
Fliar Intelligence Index™ 67how this company ranks against its industry peers
Funding
top 25%Growth
top 27%Moat
top 28%Fin. health
top 41%Market
top 43%Tech
top 45%Funding: Raised $233M across 5 rounds · 5 rounds over 10 yrs (0.5/yr) · Last round Post IPO (Feb 2025)
Growth: Headcount 30 → 72 (+140%) across vintages · Revenue +590% YoY · Web rank 10,000,000 → 50,000,000 YoY
Moat: Top 15% by revenue among 13 tracked Immunotherapy companies · Editorial + unicorn rating 6/10 · 10 curated direct competitors tracked
Audience (LinkedIn): 11k LinkedIn followers
Funding rounds
- Feb 2025Post IPO$10M
- Jan 2021Series C$95M
- Mar 2020Series B$100.5M
- Sep 2018Series A$30M
Founders & team
Investors
Takeda Ventures, SV Health Investors, MRLV, RiverVest Venture Partners, F-Prime Capital, Bay City Capital
Tech stack
Acquia Cloud PlatformAcquia Cloud Site FactoryAdobe AnalyticsAdobe Experience Platform Identity ServiceAdobe Experience Platform LaunchAkamai
#9
Series C · Cambridge, Massachusetts · founded 2020 · 103 employees$264Mraised▾
Series C · Cambridge, Massachusetts · founded 2020 · 103 employees
Developer of B cell therapies for multiple therapeutic areas. The company uses proprietary autologous and allogeneic BeCM platforms across multiple therapeutic areas and progress pipeline candidates mainly on oncology and rare diseases. Also, it advances its platform into additional therapeutic areas including infectious disease, neurological conditions, and autoimmune disease.
Fliar Intelligence Index™ 50how this company ranks against its industry peers
Funding
top 22%Moat
top 31%Market
top 48%Global
bottom 36%Funding: Raised $264M across 4 rounds · 4 rounds over 6 yrs (0.7/yr) · Last round Series C (Jan 2025)
Moat: Editorial + unicorn rating 8/10 · Soonicorn · 10 curated direct competitors tracked
Market: 103 employees (top 35% of Immunotherapy)
Audience (LinkedIn): 10k LinkedIn followers
Funding rounds
- Jan 2025Series C$92M
- Oct 2024Series B$82M
- Apr 2022Series B$130M
- Oct 2020Series A$52M
Investors
Arch Venture Partners, Atlas Venture, RA Capital Management, Alta Partners, Longwood Fund, Bristol-Myers Squibb
#10
Public · Cambridge, Massachusetts · founded 2011 · 44 employees$24.7Mraised▾
Public · Cambridge, Massachusetts · founded 2011 · 44 employees
Developing targeted and immuno-oncology therapeutics for cancer patients. Focused on advancing cancer treatment through innovative therapies, the company develops humanized monoclonal antibodies. Their pipeline includes programs targeting proteins like DKK1 and GDF-15, with clinical candidates in development for esophagogastric, gynecologic, and colorectal cancers. They are dedicated to understanding tumor expression and creating new targets and combinations. The company is committed to stopping cancer through new therapies. They are working towards expanded access for patients. The company is involved in research and development, clinical trials, and regulatory affairs.
Fliar Intelligence Index™ 35how this company ranks against its industry peers
Product
top 14%Funding
top 30%Innovation
top 34%Tech
top 49%Moat
bottom 45%News
bottom 42%Product: 4 distinct product lines · Company stage: Public
Funding: Raised $24.7M across 7 rounds · 7 rounds over 15 yrs (0.5/yr) · Last round Post IPO (Oct 2025)
Innovation: 4 product lines
Audience (LinkedIn): 6k LinkedIn followers
Funding rounds
- Oct 2025Post IPO$58.9M
- Jan 2020Post IPO$27M
- Nov 2017Post IPO$18M
- Jan 2017Series B$10M
Investors
Perceptive Advisors, BeiGene, Healthcare Ventures, Winklevoss Capital, Valence Life Sciences, Torrey Pines Investment
Tech stack
Acquia Cloud PlatformAcquia Cloud Site FactoryAdobe AnalyticsAdobe Experience Platform Identity ServiceAdobe Experience Platform LaunchAmazon Web Services
#11
Series B · Waltham, Massachusetts · founded 2023$207Mraised▾
Series B · Waltham, Massachusetts · founded 2023
Developer of functional antibodies for the treatment of immunological and inflammatory disorders. The company is pioneering a mendelian genetics-informed precision medicine which includes TRIV-509 that targets kallikreins 5 and 7 (KLK5/7), promising targets for the treatment of atopic dermatitis, asthma, and other inflammatory indications.
Funding rounds
- Oct 2024Series B$115M
- Oct 2023Series A$92M
Founders & team
Investors
Atlas Venture, Cormorant Asset Management, Orbimed, Viking Global Investors, Invus, Polaris Partners
#12
Series A · Boston, Massachusetts · founded 2023$67Mraised▾
Series A · Boston, Massachusetts · founded 2023
Developer of precision immunotherapies for autoimmune diseases. It selectively targets and depletes pathogenic immune cells, leaving healthy cells unharmed. This targeted approach aims to provide durable relief through an immune reset, unlike traditional broad immunosuppression therapies. The company's pipeline includes therapies targeting specific immune-cell subsets, offering the potential for disease remission rather than just symptom management. Development leverages antibody engineering expertise and validated modalities, focusing on identifying patient populations most likely to benefit.
LinkedIn Pulse recent public activity · Jul 2026
Audience: 4k LinkedIn followers
Hiring: 1 hiring post in 12 mo (public) · hiring: Director of Immunology
Funding rounds
- Mar 2025Series A$67M
- Aug 2023Seed—
Founders & team
Investors
Novo Holdings, Droia Ventures, Frazier Life Sciences, LifeArc Ventures, Hummingbird Bioscience
Tech stack
Apache Http ServerApple Icloud MailCookieyesGodaddyJqueryMicrosoft Advertising
Funding & investor landscape
$12.7Btotal disclosed funding
138companies funded
464disclosed rounds
1rounds last 90 days
Most active investors
Atlas Venture13 rounds
Notable founders
Geraldine Paulus
Co-Founder · Crossbow
Briggs Morrison
CEO · Crossbow
Paul-Albert König
Co-Founder and Sr. Director Biology · Odyssey
Charlie Koniver
Co-Founder · Odyssey
Garo Armen
Chairman & CEO · Agenusbio
Andrew Schiermeier
Chief Executive Officer · AvenCell
Andrew Bellinger
Co-Founder · Corner Therapeutics
Jonathan Kagan
Co-Founder & President · Corner Therapeutics
Rene Russo
CEO · Xilio Therapeutics
Vishal Patel
CEO · Triveni Bio
Robert Mabry
CEO · Hillstar Bio
Jak Knowles
Co-founder · Affini-T Therapeutics
Prism market signals · United States · country-scoped Prism corpus, 1,146,706 docs
Market landscape — 10 sub-themes by coverage
Share of Immunotherapy coverage by sub-theme.
Regulatory-risk over time falling
Funding & growth over time
funding rising · growth rising
RESEARCH IN MASSACHUSETTS · Health & Bio
How research on Immunology in Massachusetts is moving
A read on the academic research around Immunology in Massachusetts — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 443 papers.
MGH, MIT, and UMass Chan lead Massachusetts immunology research, dominated by cancer immunotherapy and CAR-T therapy, with a cautiously optimistic tone (mean stance 0.49).
443 papers · stance +0.49 · 31% breakthrough · 17% concern
top institutions
- Massachusetts General Hospital317
- Massachusetts Institute of Technology75
- University of Massachusetts Chan Medical School36
- Massachusetts Eye and Ear Infirmary15
- University of Massachusetts Amherst12
leading researchers
Ryan J. Sullivan · Marcela V. Maus · Griffin Kane · Kelly D. DeMarco · Matthew J. Frigault · Howard L. Kaufman
prism intelligence · tone & topics
96% positive · 1% critical tone
PharmaceuticalsBiotechnologyClinical TrialsMedical ResearchHealthOncology
▲
Breakthroughs125 · 28%
▲ 22%→29% share
▲1.3× share momentum0 median citations87% since 2021mostly methods-led
Chimeric antigen receptor research emerged brand-new with 18 papers, driving breakthroughs segment share from 22% to 29%.
rising sub-themes (early→recent)
- Immune system3→50
- Immunotherapy7→39
- Antigen1→16
- Tumor microenvironment1→16
- Cancer research4→19
Newly emergingChimeric antigen receptor 0→18 · Innate immune system 0→9 · Pancreatic cancer 0→7
Landmark Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders · 654 cites
◆
Advancements213 · 48%
▼ 54%→47% share
▼0.9× share momentum0 median citations82% since 2021mostly empirical
Immunotherapy advancements intensified — papers rose from 15 to 59, with Pembrolizumab newly appearing across 9 studies.
rising sub-themes (early→recent)
- Immune system10→68
- Immunotherapy15→59
- Cancer1→19
- Tumor microenvironment6→23
- T cell1→17
Newly emergingInternal medicine 0→13 · Adverse effect 0→11 · Pembrolizumab 0→9
Landmark Mechanisms of resistance to immune checkpoint inhibitors · 1,328 cites
▼
Concerns69 · 16%
▼ 17%→16% share
▼0.9× share momentum0 median citations86% since 2021mostly empirical
Immunotherapy safety concerns are rising sharply — concern-tagged papers surged from 2 to 26, with CAR-T and immune checkpoint flags newly emerging.
rising sub-themes (early→recent)
- Immunotherapy2→26
- Immune system3→16
- Cancer2→10
- Clinical trial1→7
- Immune checkpoint2→7
Newly emergingChimeric antigen receptor 0→7 · Oncology 0→7 · Disease 0→7
Landmark ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells · 3,225 cites
Common questions
How many Immunotherapy companies are there in Massachusetts, United States?
Radar tracks 183 indexable Immunotherapy companies headquartered in Massachusetts, United States that meet our profile-completeness bar.
What is the total funding raised by Immunotherapy companies in Massachusetts, United States?
The Immunotherapy companies in Massachusetts, United States on this list have raised a combined $12.7B in disclosed equity funding across 138 funded companies.
Which is the highest-funded Immunotherapy company in Massachusetts, United States?
Fog Pharmaceuticals is the highest-funded Immunotherapy company in Massachusetts, United States, with $530.9M in disclosed equity funding.
How many Immunotherapy companies in Massachusetts, United States are funded?
138 of the 183 Immunotherapy companies in Massachusetts, United States on this list have disclosed at least one equity funding round.
How many Immunotherapy unicorns are there in Massachusetts, United States?
None of the Immunotherapy companies in Massachusetts, United States on this list currently has a disclosed valuation of $1B or more.
Who are the top investors in Massachusetts, United States Immunotherapy companies?
The most active investors in Massachusetts, United States Immunotherapy companies on this list include HHS, Atlas Venture, Orbimed, Fidelity Investments, RA Capital Management.
Riya SenguptaFinancials
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.